Retina

A case study details the care of a patient who had already lost vision in one eye from a similar issue.

Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

José-Alain Sahel, MD, explains how optogenetics involves artificial photoreceptors from specific retinal cells to restore vision.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.

Ramin Tadayoni, MD, PhD, discusses the pathology of myopia around the globe.

Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

OD-OS’s teleguidance offering addresses the lack of experts and also benefits teaching in retina laser care.

Rhegmatogenous retinal detachment studied.

Development of new animal model enhances study of potential mutations.

Study examines immunomodulatory therapy as a potential long-term treatment option.

Led by eye care nonprofit Orbis with support from Alcon, the training will build eye care professionals' skills to treat retinopathy of prematurity in Latin America

Investigation evaluates safety of single and multiple intravitreal injections.

Understanding nuances of reimbursement for novel, sustained-release ophthalmic drugs can help maximize the opportunity for patients and practice.

Systemic immunosuppression may prevent devastating complication in patients.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

GT005 designed to induce local production of recombinant complement factor I.

Cotargeted therapy could help combat inherited retinal diseases.

Special to Ophthalmology Times®

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

Clinical trials show subretinal agents are safe, well tolerated by patients.

Option detects treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration

The study's finding suggest that the particles may be involved in some of the ocular clinical manifestations of the COVID-19 infection.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

Investigators have found that optical coherence tomography findings could prove to be a diagnostic tool for COVID-19.

Mitchell A. Jackson, MD, presents details of a retrospective review of dexamethasone intraocular suspension 9%, including reduced postoperative inflammation.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

This research was a finalist in the 2020 Ophthalmology Times® Research Scholar Honoree Program.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.